Lupin Limited LUPIN
Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.
Loading prices…
Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.Test a strategy on LUPIN
Real prices, every charge counted. Pick one or write your own.One of the few Indian generics makers with real strength in complex respiratory devices: it won early US approval for a generic dry powder inhaler competing with Boehringer Ingelheim's Spiriva, technology far harder to copy than a tablet. That capability sits alongside a history of US FDA warning letters across multiple plants, a recurring compliance strain many of its peers also face.
Pharmaceuticals - Generics & Respiratory
Generic and branded prescription drugs, complex inhalers and other respiratory devices, active pharmaceutical ingredients, and a large India-focused portfolio in anti-tuberculosis, diabetes, cardiovascular and respiratory medicine.
Mostly patients through pharmacies and hospitals, both in India under its own brands and in the US and other markets through generic drug distributors and health plans.
Sells branded drugs at a premium in India and generic versions of off-patent drugs at thin margins in the US and other regulated markets. Profit depends heavily on how many new generics it can launch, US price competition, and whether its plants keep passing FDA inspections.
Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.
EOD 13 NovThe share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Are its options cheap or dear?It compares the movement option prices assume with the movement the share has actually shown.
Live in market hoursImplied volatility needs the live option chain, which is open 9:15 to 3:30.
Returns and valuationWhat the market pays for this company and how well the business uses its money.
Books to 30 Sept 2026Against its sectorWhere this company ranks among similar companies on each measure.
Pharmaceuticals · 141 peers · mediansWhat the numbers sayShort plain statements about this company's latest figures.
Written by fixed rulesLatest quarterIn the quarter to September 2026 (results filed 4 Nov 2026), sales rose 11.1% from a year earlier to Rs 7,827 cr and profit fell 22.2% to Rs 1,155 cr.
- Sales grew 3 years running (Rs 15,630 cr in FY23 to Rs 27,958 cr in FY26).
- Operating margin rose from 11.8% in FY23 to 31.5% in FY26.
- No promoter shares were pledged at the end of September 2026.
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
How the share moved on resultsWhat the share price did around each recent quarterly result.
Over the last 20 results, the share rose on 6 and fell on 14, and moved by 3% or more on 7.
Q2 FY27: results filed 4 Nov 2026. The share went from its close on 3 Nov 2026 to its close on 5 Nov 2026 -1.38%.
Dividends paidCash the company has paid per share, year by year.
2026 has paid ₹18.00 per share, about ₹909 on ₹1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.
What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.
Price only, before dividendsHeld for 20 years this compounded at +16.1% a year. The last twelve months were down -0.9%. Price only, before dividends.
Who owns itThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.
Shareholding patternEach line is that holder's share of all shares over the last 6 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.
The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.
Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.
Last 6 monthsAt a glanceThe eight figures most people check first, each placed against companies in the same industry.
Against its sectorPeers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
The business, year by yearSales and net profit by financial year or by quarter.
Sales and net profitWhere every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.
FY26In FY26, of every ₹100 of sales it kept ₹19.2 as profit. Other income added ₹1.5.
How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.
Compounded a yearWhere the cash wentProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.
From the cash flow statementIn FY26 cash rose by ₹2,624 Cr, after ₹2,055 Cr spent on plant and equipment.
Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.
| Measure | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Sales growthSales in this financial year against the previous one. | -4.7% | 28.0% | 13.5% | 23.1% |
| Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax. | 11.8% | 19.0% | 23.2% | 31.5% |
| Net marginOf every ₹100 of sales in the year, how much was left as profit after everything. | 4.2% | 9.7% | 14.6% | 19.2% |
| ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money. | 5.2% | 14.4% | 20.9% | 26.9% |
| ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders. | 5.9% | 16.2% | 21.9% | 28.8% |
| Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings. | 0.34x | 0.19x | 0.29x | 0.26x |
| Interest coverHow many times the company's profit before interest could pay its interest bill. | 4.4x | 8.8x | 14.6x | 16.8x |
Each row against this company's own usual level: green better, red worse, grey close to it.
Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.
Pharmaceuticals| Company | What the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality. | How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit. | The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business. | How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money. | How much operating profit the company made on all the money in the business, whether it came from owners or lenders. | Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings. | Of every ₹100 of sales, how much is left as profit after all costs, interest and tax. | How much sales grew in the latest quarter against the same quarter a year earlier. | The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share. |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | 4.51 L cr | 41.1x | 5.0x | 14.7% | 19.1% | 0.03 | 17.8% | +11.9% | 0.85% |
| DIVISLAB Divi's Laboratories Limited | 3.04 L cr | 90.3x | 16.9x | 16.2% | 21.5% | 0.00 | 27.6% | +35.4% | 0.26% |
| TORNTPHARM Torrent Pharmaceuticals Limited | 1.78 L cr | 78.9x | 9.7x | 17.0% | 15.2% | 0.76 | 12.1% | +50.8% | 0.81% |
| LAURUSLABS Laurus Labs Limited | 1.31 L cr | 97.7x | 21.6x | 17.7% | 17.9% | 0.40 | 17.0% | +33.4% | 0.09% |
| ZYDUSLIFE Zydus Lifesciences Limited | 1.19 L cr | 28.6x | 4.3x | 18.3% | 19.9% | 0.44 | 14.1% | +29.2% | 0.08% |
| DRREDDY Dr. Reddy's Laboratories Limited | 1.15 L cr | 41.1x | 3.0x | 11.5% | 13.9% | 0.15 | 8.3% | -1.5% | 0.58% |
| CIPLA Cipla Limited | 1.12 L cr | 38.8x | 3.2x | 11.7% | 16.0% | 0.01 | 10.1% | -2.4% | 0.93% |
| MANKIND Mankind Pharma Limited | 1.09 L cr | 48.6x | 6.2x | 12.4% | 12.9% | 0.30 | 14.7% | +17.3% | 0.00% |
| AUROPHARMA Aurobindo Pharma Limited | 1.05 L cr | 26.4x | 2.7x | 9.9% | 12.8% | 0.21 | 10.8% | +23.9% | 0.38% |
| LUPIN Lupin Limited | 90,557 cr | 17.4x | 3.8x | 26.9% | 28.8% | 0.23 | 17.0% | +11.1% | 0.91% |
| GLENMARK Glenmark Pharmaceuticals Limited | 74,507 cr | 51.3x | 6.7x | 14.1% | 20.4% | 0.08 | 9.2% | -31.3% | 0.09% |
| ALKEM Alkem Laboratories Limited | 61,146 cr | 29.6x | 4.1x | 17.6% | 20.6% | 0.12 | 13.4% | +13.8% | 1.04% |
| BIOCON Biocon Limited | 59,329 cr | 216.7x | 1.7x | 1.1% | 3.0% | 0.41 | 1.9% | +2.2% | 0.14% |
| ABBOTINDIA Abbott India Limited | 56,183 cr | 34.0x | - | - | - | - | 23.0% | +11.0% | 2.48% |
| GLAND Gland Pharma Limited | 55,016 cr | 44.5x | 5.2x | 10.5% | 15.0% | 0.02 | 17.5% | +23.3% | 0.60% |
| IPCALAB IPCA Laboratories Limited | 47,798 cr | 34.1x | 5.5x | 13.2% | 16.6% | 0.06 | 14.2% | +13.8% | 0.32% |
| GLAXO GlaxoSmithKline Pharmaceuticals Limited | 45,275 cr | 40.0x | 24.1x | 48.9% | 66.5% | 0.00 | 27.6% | +20.8% | 2.13% |
| EMCURE Emcure Pharmaceuticals Limited | 44,804 cr | 41.0x | 8.4x | 19.6% | 24.8% | 0.27 | 10.7% | +24.3% | 0.15% |
| AJANTPHARM Ajanta Pharma Limited | 41,037 cr | 32.5x | 8.4x | 25.4% | 32.7% | 0.02 | 20.3% | +32.5% | 0.97% |
| SAILIFE Sai Life Sciences Limited | 40,967 cr | 108.4x | 15.2x | 15.1% | 20.9% | 0.17 | 15.9% | +22.5% | 0.00% |
| ACUTAAS Acutaas Chemicals Limited | 33,069 cr | 75.3x | 17.8x | 23.5% | 31.7% | 0.00 | 27.5% | +42.7% | 0.06% |
| WOCKPHARMA Wockhardt Limited | 32,940 cr | 80.3x | 6.4x | 4.0% | 6.5% | 0.39 | 10.8% | +23.9% | 0.00% |
| PPLPHARMA Piramal Pharma Limited | 32,557 cr | - | 4.0x | -4.0% | 0.8% | 0.69 | -2.1% | +28.1% | 0.00% |
| RUBICON Rubicon Research Limited | 27,763 cr | 85.0x | 19.6x | 19.1% | 23.4% | 0.28 | 15.5% | +39.9% | 0.09% |
| NEULANDLAB Neuland Laboratories Limited | 27,043 cr | 59.8x | 13.3x | 21.4% | 27.5% | 0.17 | 19.6% | -12.6% | 0.16% |
| APLLTD Alembic Pharmaceuticals Limited | 20,249 cr | 24.0x | 3.4x | 12.4% | 11.7% | 0.25 | 9.9% | +36.3% | 1.16% |
| GRANULES Granules India Limited | 20,151 cr | 28.1x | 3.1x | 13.5% | 15.7% | 0.09 | 12.1% | +20.3% | 0.22% |
| SHILPAMED Shilpa Medicare Limited | 19,392 cr | 58.0x | 7.0x | 9.8% | 11.4% | 0.24 | 18.1% | +43.0% | 0.06% |
| ONESOURCE Onesource Specialty Pharma Limited | 18,463 cr | - | 3.1x | -1.3% | 0.4% | 0.25 | -0.1% | +37.4% | 0.00% |
| CAPLIPOINT Caplin Point Laboratories Limited | 18,157 cr | 26.4x | 4.7x | 19.9% | 24.7% | 0.00 | 29.4% | +17.9% | 0.33% |
| ERIS Eris Lifesciences Limited | 18,116 cr | 25.4x | 4.4x | 18.1% | 13.9% | 0.58 | 21.6% | +12.6% | 0.55% |
| ALIVUS Alivus Life Sciences Limited | 17,932 cr | 26.8x | 4.9x | 18.4% | 24.6% | 0.00 | 24.9% | +16.0% | 0.34% |
| PFIZER Pfizer Limited | 17,601 cr | 20.5x | 4.0x | 17.2% | 23.4% | 0.00 | 32.4% | +13.2% | 1.95% |
| COHANCE Cohance Lifesciences Limited | 17,546 cr | 509.6x | 4.5x | 5.1% | 8.0% | 0.06 | -0.3% | -14.2% | 0.00% |
| NATCOPHARM Natco Pharma Limited | 15,898 cr | 12.7x | 1.7x | 16.9% | 17.1% | 0.08 | 32.9% | -44.7% | 0.56% |
| JUBLPHARMA Jubilant Pharmova Limited | 15,356 cr | 43.4x | 2.2x | 6.0% | 8.7% | 0.45 | 4.1% | +17.3% | 0.52% |
| ASTRAZEN AstraZeneca Pharma India Limited | 15,079 cr | 84.8x | 17.2x | 22.8% | 31.2% | 0.00 | 6.8% | +30.4% | 0.60% |
| MARKSANS Marksans Pharma Limited | 14,437 cr | 25.8x | 4.3x | 25.4% | 35.1% | 0.01 | 16.7% | +30.5% | 0.28% |
| CORONA CORONA Remedies Limited | 14,248 cr | 68.8x | 17.7x | 24.8% | 27.8% | 0.12 | 13.3% | +22.2% | 0.43% |
| CONCORDBIO Concord Biotech Limited | 12,428 cr | 44.5x | 6.0x | 13.5% | 17.9% | 0.00 | 23.9% | +25.1% | 0.63% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Month by monthThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.
Price return each month| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.0 | +6.9 | +0.5 | -0.4 | -1.6 | +6.7 | -0.2 | -9.4 | -7.2 | -0.9 | +0.2 | · | -4.5% 11m |
| 2025 | -11.7 | -8.4 | +6.5 | +3.3 | -6.6 | -1.0 | -0.5 | -1.8 | +0.9 | +2.7 | +6.0 | +1.3 | -10.4% |
| 2024 | +13.8 | +7.7 | -0.3 | +1.8 | -3.9 | +2.5 | +17.9 | +17.2 | -2.2 | -0.2 | -6.2 | +14.9 | +78.1% |
| 2023 | +0.5 | -10.6 | -1.6 | +9.4 | +13.4 | +12.2 | +9.2 | +11.4 | +6.7 | -3.7 | +13.5 | +3.3 | +80.3% |
| 2022 | -4.5 | -17.9 | +0.2 | -0.3 | -16.9 | -1.2 | +5.4 | +3.9 | +1.6 | +2.8 | +9.6 | -4.2 | -22.8% |
| 2021 | +3.1 | +1.1 | +0.2 | +4.8 | +14.0 | -5.8 | -3.6 | -13.5 | -0.7 | -3.0 | -4.2 | +7.5 | -2.6% |
| 2020 | -5.9 | -10.9 | -7.9 | +41.7 | +4.1 | +4.8 | +1.6 | +0.1 | +8.6 | -9.7 | -1.9 | +9.5 | +28.0% |
| 2019 | +3.7 | -12.8 | -3.2 | +17.9 | -14.5 | +1.2 | +1.3 | -3.1 | -3.4 | +4.1 | +7.5 | -4.7 | -9.6% |
| 2018 | -0.1 | -7.2 | -10.3 | +10.3 | -5.1 | +17.3 | -8.8 | +13.0 | -3.3 | -1.7 | +0.1 | -4.8 | -4.6% |
| 2017 | -1.1 | +0.2 | -2.0 | -7.4 | -13.3 | -8.7 | -2.6 | -5.1 | +3.5 | +1.4 | -20.5 | +8.2 | -40.5% |
Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.
Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.
| Date | Party | Side | Quantity | Price | Value |
|---|---|---|---|---|---|
| 2025-10-14 | GOLDMAN SACHS BANK EUROPE SE - ODI · block | BUY | 60,035 | ₹1,937.50 | ₹11.63 Cr |
| 2025-10-14 | GOLDMAN SACHS (SINGAPORE) PTE - ODI · block | SELL | 60,035 | ₹1,937.50 | ₹11.63 Cr |
| 2025-10-13 | GOLDMAN SACHS BANK EUROPE SE - ODI · block | BUY | 81,892 | ₹1,977.00 | ₹16.19 Cr |
| 2025-10-13 | GOLDMAN SACHS (SINGAPORE) PTE - ODI · block | SELL | 81,892 | ₹1,977.00 | ₹16.19 Cr |
| 2022-11-14 | ISHARES CORE MSCI EMERGING MARKETS ETF · block | BUY | 2,28,477 | ₹747.00 | ₹17.07 Cr |
| 2022-11-14 | ISHARES CORE EMERGING MARKETS MAURITIUS CO · block | SELL | 2,28,477 | ₹747.00 | ₹17.07 Cr |
| 2022-11-03 | ISHARES CORE MSCI EMERGING MARKETS ETF · block | BUY | 2,28,477 | ₹707.45 | ₹16.16 Cr |
| 2022-11-03 | ISHARES CORE EMERGING MARKETS MAURITIUS CO · block | SELL | 2,28,477 | ₹707.45 | ₹16.16 Cr |
- Board outcomeOutcome of Board Meeting4 Nov 2026
Lupin Limited has submitted to the Exchange, the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2026.
- Board outcomeOutcome of Board Meeting6 Aug 2026
Lupin Limited has submitted to the Exchange, Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.
- Board outcomeOutcome of Board Meeting7 May 2026
Lupin Limited has submitted to the Exchange, the Audited Financial Results for the quarter and year ended March 31, 2026 and recommendation of Final Dividend of Rs. 18 /- per equity share i.e. 900 % of the Face Value of Rs. 2/- each fully paid up for the Financial Year ended March 31, 2026.
- Board outcomeOutcome of Board Meeting12 Feb 2026
Lupin Limited has submitted to the Exchange, the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025.
- Board outcomeOutcome of Board Meeting6 Nov 2025
Lupin Limited has submitted to the Exchange about Outcome of the Board Meeting for approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and Half Year ended September 30, 2025
- Board outcomeOutcome of Board Meeting5 Aug 2025
Lupin Limited has submitted to the Exchange the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2025.
- Integrated Filing- Financial12 Feb 2025
Integrated Filing (Financial) for quarter ended December 31, 2024.
- Financial Result Updates12 Feb 2025
Lupin Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.
Read enough? Test LUPIN. “Buy LUPIN when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.
Run it free